Optimal treatment of heart failure in the elderly

Drugs and Aging

Volumn 10, Issue 6, 1997, Pages 435-443

  Doughty, Robert ^a   Andersen, Victoria ^a   Sharpe, Norman ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; CALCIUM ANTAGONIST; CAPTOPRIL; COLCHICINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

AGED; AGING; AORTA STENOSIS; CLINICAL TRIAL; COUGHING; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; GOUT; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; INCONTINENCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL;

EID: 0030927085     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199710060-00004     Document Type: Review

References (28)

1. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-7
2. Scott WG, Scott HM. Heart failure: a decision analytic analysis of New Zealand data using the published results of the SOLVD treatment trial. Pharmacoeconomics 1996; 9: 156-67
3. Doughty R, Yee T, Sharpe N, et al. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988-91. N Z Med J 1995; 108: 473-5
4. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995; 7: 10-8
5. Cody RJ. Physiological changes due to age: implications for drug therapy of congestive heart failure. Drugs Aging 1993; 3: 322-34
6. Stolarek I, Scott PJW, Caird FI. Physiological changes due to age: implications for cardiovascular drug therapy. Drugs Aging 1991; 1: 467-76
7. Mayerson M. Pharmacokinetics in the elderly. Environ Health Perspect 1994; 102 Suppl. 11: 119-24
8. Parameshwar J, Shackell MM, Richardson A, et al. Prevalence of heart failure in three general practices in north west London. Br J Gen Pract 1992; 42: 287-9
9. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72 Suppl.: S3-9
10. Wong WF, Gold S, Fukuyama O, et al. Diastolic dysfunction in elderly patients with congestive heart failure. Am J Cardiol 1989; 63: 1526-8
11. Valacio R, Lye M. Heart failure in the elderly patient. Br J Clin Pharmacol 1995; 49: 200-4
12. Barker D, Konstam M, Bortoff M, et al. Management of heart failure: I. Pharmacologic treatment. JAMA 1994; 272: 1361-6
13. Levy DW, Lye M. Diuretics and potassium in the elderly. J R Coll Physicians Lond 1987; 21: 148-52
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
16. The Acute Infarction Ramipril Efficacy (AIRE) Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
17. Pfeffer MA, Braunwald E, Moye LA, et al., on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77
18. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91
19. Cohn JN, Ziesche SM, Larrye LE, et al., and the V-HeFT Study Group. Effect of felodipine on short-term exercise and neurohormone and long-term mortality in heart failure: results of V-HeFT VIII [abstract]. Circulation 1995; 92 Suppl. 1: 1143
20. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
21. Cleland JG, Poole-Wilson PA. ACE inhibitors for heart failure: a question of dose. Br Heart J 1994; 72 (3 Suppl.): S106-10
22. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J. In press
23. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomised Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-14
24. Hammill SC, Packer DL. Amiodarone in congestive heart failure: unravelling the GESICA and CHF-STAT differences. Heart 1996; 75: 6-7
25. Cleland JGF, Morgan K. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research. Curr Opin Cardiol 1996; 11: 252-62
26. Cleland JGF, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74: 215-9
27. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91
28. Doughty RN, Sharpe N. Optimal treatment of angina in older patients. Drugs Aging 1996; 8: 349-57